We are live on
!
Find out more
PTC
Philadelphia Trust Company Portfolio holdings
AUM
$1.42B
1-Year Est. Return
43.77%
This Fund
S&P 500
This Quarter
Est. Return
+9.86%
1 Year Est. Return
+43.77%
3 Year Est. Return
+141.5%
5 Year Est. Return
+176.17%
10 Year Est. Return
+554.31%
AUM
$1.06B
AUM Growth
+$74.6M
(+7.6%)
Cap. Flow
+$2.05M
Cap. Flow
% of AUM
0.19%
Top 10 Holdings %
Top 10 Hldgs %
37.75%
Holding
243
New
12
Increased
28
Reduced
110
Closed
14
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Colgate-Palmolive
CL
|
+$8.43M |
| 2 |
WIRE
Encore Wire Corp
WIRE
|
+$5.83M |
| 3 |
Newmont
NEM
|
+$5.73M |
| 4 |
Intel
INTC
|
+$2.82M |
| 5 |
Sprott Physical Gold and Silver Trust
CEF
|
+$2.52M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Royalty Pharma
RPRX
|
+$5.26M |
| 2 |
ProShares Short QQQ
PSQ
|
+$1.72M |
| 3 |
Marathon Petroleum
MPC
|
+$1.69M |
| 4 |
Alpha and Omega Semiconductor
AOSL
|
+$1.58M |
| 5 |
Apple
AAPL
|
+$1.54M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 28.36% |
| 2 | Healthcare | 15.6% |
| 3 | Industrials | 13.26% |
| 4 | Financials | 11.63% |
| 5 | Communication Services | 6.64% |
Similar funds
CBA
BC
KC
EWS
SCM
NI
QC
IHG
Philadelphia Trust Company's Q2 2023 Portfolio in Review
As of Q2 2023, Philadelphia Trust Company held 243 positions worth $1.06B, up 7.6% from $982M the previous quarter. Its ten largest holdings account for 38% of the portfolio.
Philadelphia Trust Company's Q2 2023 filing shows 12 new, 28 increased, 110 reduced and 14 closed positions. Its largest new stake was Encore Wire Corp: 34,395 shares worth $6.39M. The largest sale was Royalty Pharma, an estimated $5.26M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, up from 25% a quarter earlier, followed by Healthcare and Industrials.
- Philadelphia Trust Company's largest Q2 2023 buy was Encore Wire Corp: 34,395 shares worth $6.39M.
- Philadelphia Trust Company added most to Colgate-Palmolive in Q2 2023, an estimated $8.43M increase.
- Philadelphia Trust Company's biggest Q2 2023 reduction was Royalty Pharma, cutting an estimated $5.26M.
- Philadelphia Trust Company fully exited ProShares Short QQQ in Q2 2023, selling an estimated $1.72M.
- Philadelphia Trust Company's ten largest holdings make up 38% of its $1.06B portfolio in Q2 2023.
- Philadelphia Trust Company opened 12 new positions and closed 14 in Q2 2023.
- Philadelphia Trust Company's portfolio value rose 7.6% quarter-over-quarter to $1.06B.
Based on Philadelphia Trust Company's 13F filing for Q2 2023, filed 7 Aug 2023.